Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06198413
PHASE1

LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Sponsor: Innostellar Biotherapeutics Co.,Ltd

View on ClinicalTrials.gov

Summary

The goal of this study is to evaluate the safety and efficacy of LX102 gene therapy for nAMD.

Official title: A Dose-Escalation Study of LX102 Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD)

Key Details

Gender

All

Age Range

50 Years - Any

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2023-02-27

Completion Date

2029-01

Last Updated

2025-07-01

Healthy Volunteers

No

Interventions

GENETIC

LX102 subretinal injection

LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap

Locations (3)

Anhui Provincial Hospital

Hefei, Anhui, China

Zhejiang University Eye Hospital

Hangzhou, Zhejiang, China

Shanghai General Hospital

Shanghai, China